The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
TT125-802, a highly selective, well-tolerated bromodomain inhibitor of CBP/p300 with anti-tumor activity in patients with advanced solid tumors: An update on the ongoing phase I study.
 
Valentina Boni
Employment - Next Oncology; Next Oncology; Quironsalud
Leadership - Next Oncology (Inst)
Stock and Other Ownership Interests - 1TRIALSP
Honoraria - Amunix; EMD Serono/Merck; Guidepoint Global; IDEAYA Biosciences; Janssen Oncology; Loxo; MSD Oncology; Puma Biotechnology
Consulting or Advisory Role - EMD Serono/Merck; Guidepoint Global; Janssen Research & Development; Lilly; Lilly; Nanobiotix; Novartis; OncoArt
Speakers' Bureau - Lilly; MSD; Solti; TACTICS; TACTICS
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Alkermes (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BioNTech (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Genmab (Inst); Incyte (Inst); Janssen Oncology (Inst); Kura Oncology (Inst); Lilly (Inst); Loxo (Inst); Menarini (Inst); Merck (Inst); Merus (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Seagen (Inst); Synthon (Inst); Tesaro (Inst); Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - Bayer; START
 
Jesús Fuentes Antrás
Employment - New Experimental Therapeutics (NEXT), Hospital Universitario Quirónsalud, Madrid, Spain
Speakers' Bureau - Sysmex
Research Funding - EUSA Pharma; Lilly; Merck KGaA
Travel, Accommodations, Expenses - Exelis
 
Elena Garralda
Employment - Next Oncology
Stock and Other Ownership Interests - 1TRIALSP
Consulting or Advisory Role - Abbvie; Alentis Therapeutics; Amgen; Anaveon; Astex Pharmaceuticals; Boehringer Ingelheim; Daiichi Sankyo/Lilly; Ellipses Pharma; Genmab; Gilead Sciences; Greywolf; Hengrui Therapeutics; Incyte; Janssen; Marengo Therapeutics; Medpace; Medscape; Pfizer; Roche; Sanofi; Seagen; Skypta; Sotio
Speakers' Bureau - AEFI; Alcura; Aran; AstraZeneca; CDDF; Doctaforum; ESMO; Fundación ECO; Fundación SEOM; Horizon CME; Karger Publishers; Medscape; MeetingPharma; MSD; Novartis; PPD Global; Roche; Seagen; Springer Nature; Tactics; The Ricky Rubio Fundation
Research Funding - Anaveon; AstraZeneca/MedImmune (Inst); BeiGene (Inst); Janssen (Inst); Novartis (Inst); Roche (Inst); Taiho Oncology (Inst); Thermo Fisher Scientific (Inst)
Other Relationship - Adaptimmune (Inst); Affimed Therapeutics (Inst); Amgen (Inst); Anaveon (Inst); AstraZeneca (Inst); Bicycle Therapeutics (Inst); Bioinvent (Inst); BioNTech (Inst); Boehringer Ingelheim (Inst); Catalym (Inst); Cyclacel (Inst); CytomX Therapeutics (Inst); Cytovation (Inst); F-Star Beta Limited (Inst); F. Hoffmann LaRoche (Inst); Genentech (Inst); Genmab (Inst); HiFiBiO Therapeutics (Inst); Hutchison MediPharma (Inst); Imcheck Therapeutics (Inst); Immunocore (Inst); Incyte (Inst); Janssen-Cilag SA (Inst); MedImmune (Inst); Merck KGaA (Inst); Novartis (Inst); Peptomyc (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Replimune (Inst); Ribon Therapeutics (Inst); Roche (Inst); Ryvu Therapeutics (Inst); Seagen (Inst); SERVIER (Inst); Sotio (Inst); SQZ Biotech (Inst); Symphogen (Inst); T-Knife (Inst); Taiho Pharmaceutical (Inst)
 
Omar Saavedra
No Relationships to Disclose
 
Ilaria Colombo
Employment - Medtronic (I)
Stock and Other Ownership Interests - Medtronic (I)
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst); BioNTech SE; GlaxoSmithKline (Inst); Incyte (Inst); MSD Oncology (Inst)
Speakers' Bureau - Abbvie (Inst); GlaxoSmithKline; GlaxoSmithKline (Inst)
Research Funding - Incyte (Inst); Merck KGaA (Inst); MSD (Inst); Oasmia Pharmaceutical AB (Inst); Orion Clinical (Inst); Tolremo (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline
 
Martina Imbimbo
No Relationships to Disclose
 
Irene Brana
Consulting or Advisory Role - AstraZeneca; Bicara Therapeutics; Boehringer Ingelheim; Boehringer Ingelheim Spain; Cancer Expert Now; Gilead Sciences; Merck Sharp & Dohme; Merus
Speakers' Bureau - Bristol-Myers Squibb; Merck Serono; MSD
Research Funding - AOP Health (Inst); AstraZeneca (Inst); Bicara Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Debiopharm Group (Inst); Dragonfly Therapeutics (Inst); Epizyme (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gliknik (Inst); Hookipa Pharma (Inst); IDEAYA Biosciences (Inst); Immutep (Inst); ISA Pharmaceuticals (Inst); Janssen Oncology (Inst); Kura Oncology (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Nanobiotix (Inst); Northern Biologics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Regeneron (Inst); Roche (Inst); Seagen (Inst); Seagen (Inst); Shattuck Labs (Inst); Tango Therapeutics (Inst); Tolremo (Inst); VCN Biosciences (Inst)
 
Gaspar Joaquin Molina Lores
No Relationships to Disclose
 
Krisztian Homicsko
Research Funding - BMS Global; MSD; Owkin (Inst); ROCHE; TOLREMO
 
Dorothea Gruber
Employment - Tolremo
Stock and Other Ownership Interests - Tolremo
Patents, Royalties, Other Intellectual Property - Tolremo
 
Silvio Costanzo
Employment - Anaveon; TOLREMO therapeutics AG
Stock and Other Ownership Interests - Anaveon; TOLREMO therapeutics AG
 
Alessandra Cesano
Employment - ESSA
Leadership - Puma Biotechnology; Summit Therapeutics; Zymeworks
Stock and Other Ownership Interests - Puma Biotechnology; Summit Therapeutics; Zymeworks
Consulting or Advisory Role - Actym Therapeutics; Biograph55; SV20; Tolremo
 
Stefanie Flückiger-Mangual
Employment - Abbott Laboratories (I); Covis Pharma (I); TOLREMO therapeutics AG
Leadership - Tolremo
Stock and Other Ownership Interests - Abbott Laboratories (I); Tolremo
Patents, Royalties, Other Intellectual Property - Patent holder
Travel, Accommodations, Expenses - Abbott Laboratories (I); Tolremo